Prescription based, and already pre-approved by insurance companies to cover the costs at these prices.
For cosmetic reasons is the only reason a person will have to pay out of pocket, and these people are never accounted for in company figures and will be yet another wildcard to add to the overall sales figure one day.
BOT is a goldmine in the making for us early holders...and its still early for those on the fence, like not even on the starting block for what's to come.
Good luck on the 20th holders, it's going to be a blast
- Forums
- ASX - By Stock
- BOT
- Sofdra US Sales Curve
BOT
botanix pharmaceuticals ltd
Add to My Watchlist
9.68%
!
34.0¢

Sofdra US Sales Curve, page-6
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
34.0¢ |
Change
0.030(9.68%) |
Mkt cap ! $666.7M |
Open | High | Low | Value | Volume |
31.0¢ | 35.0¢ | 31.0¢ | $3.702M | 11.12M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 278570 | 33.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 50000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 257100 | 0.335 |
8 | 371349 | 0.330 |
6 | 263690 | 0.325 |
6 | 290115 | 0.320 |
7 | 489887 | 0.315 |
Price($) | Vol. | No. |
---|---|---|
0.345 | 115000 | 3 |
0.350 | 149326 | 6 |
0.355 | 153000 | 3 |
0.360 | 83860 | 6 |
0.370 | 260842 | 4 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online